This article has been updated from a previous version as Qiagen clarified an earlier statement regarding its acquisition of PrimeraDx.

NEW YORK (GenomeWeb) — Qiagen said today that it is collaborating with Eli Lilly to co-develop universal and modular assay panels to simultaneously analyze DNA and RNA biomarkers targeting multiple cellular pathways in common cancer types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.